Home > News > Nanotech Disappoints in Europe
July 6th, 2007
Nanotech Disappoints in Europe
Anxious investors are but one of the problems plaguing nanotechnology, the cutting-edge science of manipulating materials and microscopic devices at the atomic level.
Consider the story of Oxonica, Britain's highest-profile publicly traded nanotech startup. It revealed in late April that one of its key products—a catalyst designed to cut vehicle emissions when combined with high-sulfur diesel fuel—didn't work as expected, leading to the cancellation of a big supply deal with Turkish oil retailer Petrol Ofisi.
Oxonica shares were suspended until June, but when trading began again, the price plunged nearly 75%, wiping out $80.7 million in Oxonica's market capitalization. To save face, the company noted that Petrol Ofisi had agreed to work with it on another project involving low-sulfur diesel. But the damage was done, and Oxonica's share price is still only half what it was in April.
TARA Biosystems and Harris & Harris Group Form Company to Improve Safety and Efficacy of New Therapies October 22nd, 2014
Arrowhead Issues Open Letter to Shareholders October 9th, 2014
PEN Inc. Announces New Trading Symbol: PENC: Stock Continues Trading on the OTCQB September 3rd, 2014
Aspen Aerogels, Inc. to Present at Barclays CEO Energy-Power Conference August 27th, 2014
Mechanism behind nature's sparkles revealed October 22nd, 2014
Special UO microscope captures defects in nanotubes: University of Oregon chemists provide a detailed view of traps that disrupt energy flow, possibly pointing toward improved charge-carrying devices October 21st, 2014
Could I squeeze by you? Ames Laboratory scientists model molecular movement within narrow channels of mesoporous nanoparticles October 21st, 2014
Detecting Cancer Earlier is Goal of Rutgers-Developed Medical Imaging Technology: Rare earth nanocrystals and infrared light can reveal small cancerous tumors and cardiovascular lesions October 21st, 2014